Literature DB >> 17402720

Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.

Michael Groessl1, Erwin Reisner, Christian G Hartinger, Rene Eichinger, Olga Semenova, Andrei R Timerbaev, Michael A Jakupec, Vladimir B Arion, Bernhard K Keppler.   

Abstract

Imidazolium [trans-tetrachloro(1H-imidazole)(S-dimethylsulfoxide)ruthenate(III)] (NAMI-A) and indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) are the most promising ruthenium complexes for anticancer chemotherapy. In this study, the azole ligand of NAMI-A was systematically varied (from imidazole of NAMI-A to indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole), and the respective complexes were evaluated with regard to the rate of aquation and protein binding, redox potentials, and cytotoxicity by means of capillary zone electrophoresis, electrospray ionization mass spectrometry, cyclic voltammetry, and colorimetric microculture assays. Stability studies demonstrated low stability of the complexes at pH 7.4 and 37 degrees C and a high reactivity toward proteins (binding rate constants in the ranges of 0.02-0.34 and 0.01-0.26 min-1 for albumin and transferrin, respectively). The redox potentials (between 0.25 and 0.35 V) were found to be biologically accessible for activation of the complexes in the tumor, and the indazole-containing compound shows the highest antiproliferative activity in vitro.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17402720     DOI: 10.1021/jm061081y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  Microwave synthesis of mixed ligand diimine-thiosemicarbazone complexes of ruthenium(II): biophysical reactivity and cytotoxicity.

Authors:  Floyd A Beckford; Michael Shaloski; Gabriel Leblanc; Jeffrey Thessing; Lesley C Lewis-Alleyne; Alvin A Holder; Liya Li; Navindra P Seeram
Journal:  Dalton Trans       Date:  2009-09-28       Impact factor: 4.390

2.  Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes.

Authors:  Leonor Côrte-Real; Filipa Mendes; Joana Coimbra; Tânia S Morais; Ana Isabel Tomaz; Andreia Valente; M Helena Garcia; Isabel Santos; Manuel Bicho; Fernanda Marques
Journal:  J Biol Inorg Chem       Date:  2014-02-23       Impact factor: 3.358

3.  Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.

Authors:  Michael Groessl; Yury O Tsybin; Christian G Hartinger; Bernhard K Keppler; Paul J Dyson
Journal:  J Biol Inorg Chem       Date:  2010-03-07       Impact factor: 3.358

4.  Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.

Authors:  Golara Golbaghi; Irène Pitard; Matthieu Lucas; Mohammad Mehdi Haghdoost; Yossef López de Los Santos; Nicolas Doucet; Shunmoogum A Patten; J Thomas Sanderson; Annie Castonguay
Journal:  Eur J Med Chem       Date:  2020-01-03       Impact factor: 6.514

5.  Screening organometallic thiophene containing thiosemicarbazone ruthenium (II/III) complexes as potential anti-tumour agents.

Authors:  Zehra Tavsan; Pelin Köse Yaman; Elif Subasi; Hulya Ayar Kayali
Journal:  J Biol Inorg Chem       Date:  2018-03-22       Impact factor: 3.358

6.  Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.

Authors:  Maria G Mendoza-Ferri; Christian G Hartinger; Marco A Mendoza; Michael Groessl; Alexander E Egger; Rene E Eichinger; John B Mangrum; Nicholas P Farrell; Magdalena Maruszak; Patrick J Bednarski; Franz Klein; Michael A Jakupec; Alexey A Nazarov; Kay Severin; Bernhard K Keppler
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

7.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

8.  The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.

Authors:  Malgorzata Brindell; Iwona Stawoska; Justyna Supel; Andrzej Skoczowski; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2008-04-26       Impact factor: 3.358

9.  Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.

Authors:  Angela Casini; Guido Mastrobuoni; Mattia Terenghi; Chiara Gabbiani; Enrico Monzani; Gloriano Moneti; Luigi Casella; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2007-08-07       Impact factor: 3.358

10.  X-ray fluorescence imaging of single human cancer cells reveals that the N-heterocyclic ligands of iodinated analogues of ruthenium anticancer drugs remain coordinated after cellular uptake.

Authors:  Sumy Antony; Jade B Aitken; Stefan Vogt; Barry Lai; Tracey Brown; Leone Spiccia; Hugh H Harris
Journal:  J Biol Inorg Chem       Date:  2013-08-14       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.